Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026410 · ClinicalTrials.gov registry record · Phase 1
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Kura Oncology.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06026410: Recruiting Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Kura Oncology.
NCT06026410 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC) that is actively recruiting participants, run by Kura Oncology. The registered enrollment target is 300 participants, roughly in line with the 280-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06026410, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Kura Oncology.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Conditions Studied
Interventions
- DRUG Darlifarnib
- DRUG Cabozantinib
- DRUG Adagrasib
Study Locations (20)
California
- University of Southern California - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Department of Medicine - Los Angeles
Florida
- AdventHealth Celebration - Celebration
- Mayo Clinic Comprehensive Cancer Center - Jacksonville
- Florida Cancer Specialists - Sarasota
Texas
- UT Southwestern Simmons Cancer Center - Dallas
- MD Anderson Cancer Center - Houston
Arizona
- Mayo Clinic Comprehensive Cancer Center - Phoenix
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Iowa
- University of Iowa Hospitals & Clinics - Iowa City
Massachusetts
- Dana-Farber Cancer Institute - Boston
Michigan
- Henry Ford Health System - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-10-18 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What NCT06026410 shows while recruiting
NCT06026410 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 280-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target.
The record links to 7 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which Darlifarnib is the first listed.
NCT06026410 names 20 study sites across 15 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06026410 about?
NCT06026410 is a clinical study titled "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors". This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
What is the current status of trial NCT06026410?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 300 participants. The study started on 2023-10-18. Estimated completion is 2027-04.
What conditions does trial NCT06026410 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Clear Cell Renal Cell Carcinoma (ccRCC), Renal Cell Carcinoma (Kidney Cancer).
What interventions are being tested in trial NCT06026410?
The interventions under investigation include: Darlifarnib (DRUG), Cabozantinib (DRUG), Adagrasib (DRUG).
Who is sponsoring clinical trial NCT06026410?
This trial is sponsored by Kura Oncology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06026410 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06026410's enrollment target sits among peer trials
300 21st of 59 higher than 38 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI